BACKGROUND
Patient reported outcomes (PROs) are an accepted and often actively solicited source of evidence used by health authorities and payers in evaluating and approving pharmaceutical interventions in addition to demonstration of the efficacy and safety of the intervention. There is, however, limited information on how payers value PRO data in reimbursement decisions. The clinical evidence section of value dossiers often include PRO data while health related quality of life (HRQoL) data is often incorporated into cost effectiveness analyses of economic models. A multitude of endpoints and variation in how payers in different countries assess evidence makes it difficult to understand the value of PRO data in reimbursement decisions. An assessment was undertaken to gauge the current and future impact of PRO data on health care decision making in centralized markets, specifically in the oncology therapeutic area.
OBJECTIVE
• To determine the impact of PRO data from clinical trial programs on market access decision making in oncology and other disease areas in centralized markets.
METHODS
• PubMed/MEDLINE, Embase, ISPOR databases, and regulatory and health technology assessment (HTA) websites for the EMA, the UK, France, and Germany were searched to identify PRO data included in regulatory and HTA submissions of four oncology drugs: bevacizumab, pemetrexed, sunitinib, and crizotinib. One-on-one interviews were conducted with 10 payer/decision makers ('payers') from different countries with centralized healthcare systems in 2014. An online assessment was conducted (December 8, 2014 , to March 4, 2015 with 5 completed surveys (China, France, Germany, Taiwan, the UK) and 2 partially completed surveys (Australia and South Korea) by payers from the RTI Health Solutions Global Payer Advisory Panel.
• The profiles of the payers and payer advisors interviewed are listed in Table 1 . All ten respondents were professors of health economics. 
RESULTS
When asked "what the role of PRO data in market access decision making is", respondents indicated:
"The key role of PROs is getting to the key bit of QALYs [quality of life years] in terms of measurement of utility. They would also like to see symptom or disease specific measures to confirm and support evidence and direction of measures of utility, but they are subsidiary."
"PRO measures have a minor role in overall HTA [Health Technology Assessment] and market decision process -it is additional information that we would like to see for incremental benefit. The most important dimensions are the severity of the condition (for oncology this is not a problem), efficacy, safety and then other dimensions such as unmet needs, mode of administration, mode of action and then QOL. PROs are related to QOL. In the future we expect that PROs will gain some importance."
Germany United Kingdom
"PRO is included in the reimbursement decision. In HE [Health Evaluation] (cost per QALY) -there is willingness to pay more for severe diseases -hence need QOL data for this. In some cases, companies have also used willingness to pay studies for supporting reimbursement." When asked "to rate the level of importance given to PRO data for market access of new oncology treatments"
France
• on a scale of 1 to 7 where 1 means 'not important' and 7 means 'extremely important', the average rating was 4.5 (Figure 1 ). Figure 1 : Rating of the level of importance given to PRO data Rating Rating A u s t r a l i a F r a n c e G e r m a n y K o r e a N e t h e r l a n d s P o l a n d S w e d e n T a i w a n T u r k e y Rated on a scale of 1 to 7 where 1 means "not at all useful" and 7 means "extremely useful"
"…there is a willingness to pay more for severe diseases…[we] need QoL data for this."
"Cancer is a special area of concern in the Turkish healthcare system, because it's really sensitive to say no to a cancer drug…That's why PRO data is not that important…."
Sweden South Korea
Turkey "PRO can move the needle. Really need to publish and educate payers about PROs outside of QALYs."
When asked to describe the specific characteristics that a PRO endpoint for treatment in oncology should have, respondents listed the following:
• Validated, objective, reliable measurements that encompass a broad range of effects and symptoms and are relevant to all patients receiving treatment Respondents indicated that PRO data is more useful in the evaluation of chronic or palliative therapy options and that overall the importance of PRO data will increase in the future.
• Overall, the respondents indicated that PRO measures had value in clinical trials of oncology therapies.
• PRO data should optimally be collected in Phase 3 and post-marketing trial data with emphasis on comparator trial data and real world clinical experience.
• PRO data are very important, especially in the advanced metastatic stage of cancer • There were minimal differences in the usefulness of PRO measures by cancer indication.
• Assessment of symptoms and health-related QoL were consistently ranked as the PRO measures with greatest value (Figure 2) • PRO data has the greatest impact at the local level where positive data could impact uptake, reimbursement, and market share. Payer's advice for pharmaceutical manufacturers with respect to communicating PRO evidence to decision makers:
Integrate "…[provide] more information to key opinion leadersthey can have a big impact on decision makers…."
"…if the PRO analysis is made in a different culture, you cannot translate the results to another culture easily….if you are talking about caregiver burden, it's quite different in different cultures."
Turkey "PRO data should be only used to support and to translate (as viewed from the patients) the clinical benefits of the treatment. If you don't have an effective drug, forget PROs."
France Poland
Validate "provide the data in a way that's convincing with respect to its rigor and [that] is representative of the patient's journey…show that it has been collected in a way that is rigorous and provides true insight into that experience."
"Adoption by the US and Europe is key…if information is available from FDA or EMA then we trust it more…"
"-analyze data with care and use high quality measures that are valid…early modeling of where the utility gain is going to come from enables you to see at which stage in the disease the main utility gain is going to come from. Publications of the key date are useful…"
United Kingdom

Australia
Taiwan
Educate "the prescribers are not used to PRO data and they need to be educated…" "…inform clinicians of the PRO and other clinical data. They are the ones who will be called upon…as consultants. This is an important avenue for reimbursement."
"show [PRO data] to clinicians. This is the flow of information: manufacturer → clinicians → reimbursement authority"
Sweden
Korea
Netherlands
CONCLUSIONS
• Currently, inclusion of PRO data in reimbursement decision making varies by country and within country by payer type: national, regional, local decision-maker
• There are minimal requirements or guidelines currently available addressing whether and how health care decision makers use PRO evidence
• There is a growing recognition that the patient perspective is important to decisions regarding market access in centralized markets and may be a key differentiator among therapeutic options
• Effective PRO data should be collected using validated methods that emulate real world clinical experience and published in peerreviewed journals
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